Cơ Chế Tác Dụng :
REN-850 is an oral drug for multiple sclerosis which is in Phase I of clinical trials.
REN-850 acts by inhibiting leukocyte trafficking and modulating the cell migration driven by multiple chemokine receptors. The oral administration of REN-850 significantly reduces severity of outcomes in multiple in vivo models of multiple Sclerosis (MS) and rheumatoid arthritis (RA).
Chỉ Định :
Investigated for use/treatment in multiple sclerosis.